Evidence map›Paper›PMID 16446752›Full record

Trial reportThe pharmacogenomics journal

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.

M E Risner, A M Saunders, J F B Altman, G C Ormandy, S Craft, I M Foley, M E Zvartau-Hind, D A Hosford, A D Roses, Rosiglitazone in Alzheimer's Disease Study Group

Registry-linked trialAbstract readClinical TrialComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Trial report in The pharmacogenomics journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02409238. Cited by 312 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
312citing papers in PubMed, 9 pooled it
30.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02409238 phase4terminated

Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled Trial

Ran2015Enrolled105Registered outcomes16Posted comparisons0ConditionsDiabetes Mellitus, Type 2, Insulin Resistance, Mild Cognitive ImpairmentArmsIntensive Lifestyle Intervention, Metformin, Standard LIfestyle Recommendation
PMID 20452916PMID 24577463PMID 24357209PMID 20733306PMID 21592048PMID 25537705PMID 25537706PMID 16286438PMID 18602098PMID 20435794other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

312 citing papers in PubMed, 9 syntheses or guidelines pooled it, 681 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Review
  16. Observational
  17. Article
  18. Review
  19. Review
  20. Review

252 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

M E RisnerWorld Wide Development, Research and Development, GlaxoSmithKline, Research Triangle Park, NC 27709-3398, USA. Marc.E.Risner@gsk.com
A M Saunders
J F B Altman
G C Ormandy
S Craft
I M Foley
M E Zvartau-Hind
D A Hosford
A D Roses
Rosiglitazone in Alzheimer's Disease Study Group
GlaxoSmithKline (United Kingdom) · GBGlaxoSmithKline (United States) · USResearch Triangle Park Foundation · USUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mild-to-moderate AD patients were randomized to placebo or rosiglitazone (RSG) 2, 4 or 8 mg. Primary end points at Week 24 were mean change from baseline in AD Assessment Scale-Cognitive (ADAS-Cog) and Clinician's Interview-Based Impression of Change Plus Caregiver Input global scores in the intention-to-treat population (N=511), and results were also stratified by apolipoprotein E (APOE) genotype (n=323). No statistically significant differences on primary end points were detected between placebo and any RSG dose. There was a significant interaction between APOE epsilon4 allele status and ADAS-Cog (P=0.014). Exploratory analyses demonstrated significant improvement in ADAS-Cog in APOE epsilon4-negative patients on 8 mg RSG (P=0.024; not corrected for multiplicity). APOE epsilon4-positive patients did not show improvement and showed a decline at the lowest RSG dose (P=0.012; not corrected for multiplicity). Exploratory analyses suggested that APOE epsilon4 non-carriers exhibited cognitive and functional improvement in response to RSG, whereas APOE epsilon4 allele carriers showed no improvement and some decline was noted. These preliminary findings require confirmation in appropriate clinical studies.

Indexed as

AgedAllelesAlzheimer DiseaseApolipoprotein E4Apolipoproteins ECognitionDose-Response Relationship, DrugFemaleGenotypeHumansHypoglycemic AgentsMalePharmacogeneticsRosiglitazoneThiazolidinedionesApolipoprotein E4Apolipoproteins EHypoglycemic AgentsRosiglitazoneThiazolidinediones

Identifiers

PMID16446752
OpenAlexW2099271519

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.